Cargando…

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major health burden due to its increasing incidence and poor prognosis. PDAC is characterized by a low tumor mutational burden, and its molecular pathogenesis is driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. Response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rémond, M.S., Pellat, A., Brezault, C., Dhooge, M., Coriat, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674888/ https://www.ncbi.nlm.nih.gov/pubmed/36399952 http://dx.doi.org/10.1016/j.esmoop.2022.100638

Ejemplares similares

Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
por: Lellouche, Lisa, et al.
Publicado: (2021)

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
por: Lellouche, Lisa, et al.
Publicado: (2023)

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
por: Falette Puisieux, Manon, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
por: Palmieri, Lola-Jade, et al.
Publicado: (2020)

Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment
por: Pellat, Anna, et al.
Publicado: (2022)

Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients
por: Dréanic, Johann, et al.
Publicado: (2015)

Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
por: Pellat, Anna, et al.
Publicado: (2021)

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
por: Huffman, Brandon M., et al.
Publicado: (2022)

Updates on the Treatment of Pancreatic Diseases: Focus on Surgery, Electrochemotherapy and Rituximab
por: Coriat, Romain, et al.
Publicado: (2022)

Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
por: Pellat, Anna, et al.
Publicado: (2020)

Self-expandable metal stent through the tumor to treat an intestinal obstruction due to pancreatic squamous cell carcinoma
por: Soliman, Heithem, et al.
Publicado: (2017)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
por: Daniel, S. K., et al.
Publicado: (2019)

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
por: Keller, Hilary R., et al.
Publicado: (2017)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
por: Rawla, Prashanth, et al.
Publicado: (2019)

Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
por: Hester, Robert, et al.
Publicado: (2021)

Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
por: Marchese, Ugo, et al.
Publicado: (2022)

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
por: Pellat, Anna, et al.
Publicado: (2021)

Recent advances in targeted therapy for pancreatic adenocarcinoma
por: Fang, Yu-Ting, et al.
Publicado: (2023)

A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy
por: Atiq, Saad, et al.
Publicado: (2021)

B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy
por: Chen, Xin, et al.
Publicado: (2022)

The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
por: Valkema, M. J., et al.
Publicado: (2022)

Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years
por: Pellat, Anna, et al.
Publicado: (2022)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)

Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
por: Kawakubo, Kazumichi, et al.
Publicado: (2022)

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021)

Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
por: Rager, Taylor, et al.
Publicado: (2022)

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
por: Bowers, Jacob S., et al.
Publicado: (2019)

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer
por: Pellat, Anna, et al.
Publicado: (2022)

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
por: Lee, Michael K. C., et al.
Publicado: (2021)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
por: Kung, Heng‐Chung, et al.
Publicado: (2023)

Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
por: Doumbe-Mandengue, Paul, et al.
Publicado: (2022)

Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma
por: Patil, Neha R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nl5elqcurg834i0cgr0vjepsi9